Repare Therapeutics ( (RPTX) ) just unveiled an update.
Repare Therapeutics announced positive results from its MYTHIC Phase 1 clinical trial, showing promising outcomes for the combination of lunresertib and camonsertib in treating endometrial and platinum-resistant ovarian cancers. The trial demonstrated favorable tolerability and response rates, supporting plans for a Phase 3 trial in 2025, marking a significant step forward in potential new treatment options for patients with these challenging cancer profiles.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies using its proprietary synthetic lethality approach. The company employs its genome-wide, CRISPR-enabled SNIPRx platform to create novel therapeutics aimed at treating cancers with precision.
YTD Price Performance: -50.68%
Average Trading Volume: 149,154
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $153M
See more insights into RPTX stock on TipRanks’ Stock Analysis page.